Journal article
The European General Data Protection Regulation: Challenges and considerations for iPSC researchers and biobanks
M Morrison, J Bell, C George, S Harmon, M Munsie, J Kaye
Regenerative Medicine | FUTURE MEDICINE LTD | Published : 2017
Open access
Abstract
Increasingly, human induced pluripotent stem cells (iPSC) and their associated genetic and clinical information are being used in a wide range of applications, with large biobanks being established to support and increase their scientific use. The new European General Data Protection Regulations, which comes into effect in 2018, will have implications for biobanks that generate, store and allow research access to iPSC. This paper describes some of the challenges that iPSC biobanks face and suggests some points for the development of appropriate governance structures to address these new requirements. These suggestions also have implications for iPSC research in general.
Grants
Awarded by European Federation of Pharmaceutical Industries and Associations
Funding Acknowledgements
M Morrison is funded by the ESRC project grant ES/P002943/1 "Biomodifying technologies and experimental space." For C George and S Harmon, the research leading to these results has received funding from the Innovative Medicines Initiative Joint Undertaking under Grant Agreement No 115582-EBiSC (European Bank for induced pluripotent Stem Cells); resources of which are composed of financial contribution from the EU's Seventh Framework Program (FP7/2007-2013) and EFPIA companies in kind contribution. J Kaye is funded by Wellcome Trust award 096599/2/11/Z which includes provision for paying open access fees. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.